BUILD 3: Bosentan Use in Interstitial Lung Disease (BUILD 3)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00391443 |
Recruitment Status :
Completed
First Posted : October 24, 2006
Results First Posted : May 25, 2012
Last Update Posted : September 28, 2015
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Idiopathic Pulmonary Fibrosis | Drug: Bosentan Drug: Placebo | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 616 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study. |
Study Start Date : | February 2007 |
Actual Primary Completion Date : | February 2010 |
Actual Study Completion Date : | July 2010 |

Arm | Intervention/treatment |
---|---|
Experimental: Bosentan
Subjects receive bosentan 62.5 mg twice daily (b.i.d.) for 4 weeks followed by bosentan 125 mg b.i.d (if body weight > 40 kg) or bosentan 62.5 mg b.i.d. (if body weight < 40 kg)
|
Drug: Bosentan
Bosentan 62.5 mg tablets twice daily (b.i.d.) for 4 weeks followed by bosentan 125 mg tablets b.i.d (if body weight > 40 kg) or bosentan 62.5 mg tablets b.i.d. (if body weight < 40 kg)
Other Names:
|
Placebo Comparator: Placebo
Subjects receive placebo matching the bosentan treatment regimen
|
Drug: Placebo
Placebo matching bosentan 62.5 mg tablets and 125 mg tablets |
- Time to Occurrence of Disease Worsening or Death up to End of Study. [ Time Frame: 36 months ]Disease worsening was defined as an event of worsening of pulmonary function tests (PFT) or acute exacerbation of idiopathic pulmonary fibrosis (IPF).
- Percentage of Patients Who Experienced Either Disease Worsening or Death at 1 Year. [ Time Frame: 12 months ]Disease worsening was defined as an event of worsening of pulmonary function tests (PFT) or acute exacerbation of idiopathic pulmonary fibrosis (IPF).

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Signed informed consent
- Male or female aged 18 years or older (females of child-bearing potential must have been surgically sterilized or use a reliable method of contraception.)
- Proven diagnosis of IPF according to American Thoracic Society / European Respiratory Society (ATS-ERS) statement, of <3 years, with surgical lung biopsy (SLB)
Exclusion Criteria:
- Interstitial lung disease due to conditions other than IPF.
- Presence of extensive honeycombing (HC) on baseline high-resolution computed tomography (HRCT) scan.
- Severe concomitant illness limiting life expectancy (<1 year).
- Severe restrictive lung disease.
- Obstructive lung disease.
- Diffusing capacity of the lung for carbon monoxide <30% predicted.
- Residual volume > or = 120% predicted.
- Documented sustained improvement of patient's IPF condition up to 12 months prior to randomization with or without IPF-specific therapy.
- Recent pulmonary or upper respiratory tract infection (up to 4 weeks prior to randomization).
- Acute or chronic impairment (other than dyspnea) limiting the ability to comply with study requirements.
- Chronic heart failure with New York Heart Association (NYHA) class III/IV or known left ventricular ejection fraction <25%.
- Alanine aminotransferase (ALT/SGPT) and/or aspartate aminotransferase (AST/SGOT) > 1.5 times the upper limit of the normal ranges.
- Moderate to severe hepatic impairment.
- Serum creatinine > or = 2.5 mg/dl or chronic dialysis.
- Hemoglobin concentration <75% the lower limit of the normal ranges.
- Systolic blood pressure <85 mmHg.
- Pregnancy or breast-feeding.
- Current drug or alcohol dependence.
- Chronic treatment with the following drugs prescribed for IPF (within 4 weeks of randomization):oral corticosteroids (>20 mg/day of prednisone or equivalent), immunosuppressive or cytotoxic drugs, antifibrotic drugs, chronic use of N-acetylcysteine (prescribed for IPF).
- Oral anticoagulants other than those indicated for a venous or arterial thrombotic disease.
- Treatment with glibenclamide (glyburide) and calcineurin inhibitors (cyclosporine A, tacrolimus) up to 1 week prior to randomization.
- Treatment with an endothelin receptor antagonist up to 3 months prior to randomization.
- Participation in the BUILD 1 trial.
- Treatment with another investigational drug up to 3 months prior to randomization or planned treatment.
- Known hypersensitivity to bosentan or any of the excipients.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00391443

Study Director: | Isabelle Leconte | Actelion |
Responsible Party: | Actelion |
ClinicalTrials.gov Identifier: | NCT00391443 |
Other Study ID Numbers: |
AC-052-321 |
First Posted: | October 24, 2006 Key Record Dates |
Results First Posted: | May 25, 2012 |
Last Update Posted: | September 28, 2015 |
Last Verified: | August 2015 |
BUILD 3 Idiopathic Pulmonary Fibrosis Tracleer |
Interstitial Lung Disease bosentan Actelion |
Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis Fibrosis Pathologic Processes Lung Diseases |
Respiratory Tract Diseases Bosentan Antihypertensive Agents Endothelin Receptor Antagonists Molecular Mechanisms of Pharmacological Action |